Market Insights Health Pharmaceuticals Vaccines

Other Vaccines - South America

South America

The revenue in the Other Vaccines market in South America is forecasted to reach US$1.46bn in 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2029) of 10.54%, leading to a market volume of US$2.41bn by 2029.
When compared globally, United States is projected to generate the highest revenue of US$24,730.00m in 2024.
South America is experiencing a growing demand for other vaccines as the region focuses on expanding its immunization programs.

Key regions: Australia, Brazil, United Kingdom, Europe, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Other Vaccines market in South America has been experiencing significant growth in recent years.

Customer preferences: South American customers are becoming increasingly aware of the importance of vaccination and are seeking out a wider variety of vaccines to protect themselves and their families. In addition, government vaccination campaigns are driving demand for Other Vaccines in the region.

Trends in the market: Brazil and Argentina are the largest markets for Other Vaccines in South America. The market is expected to continue to grow due to increasing demand and a growing number of local manufacturers producing these vaccines. In addition, there is a trend towards combination vaccines, which offer protection against multiple diseases in a single shot.

Local special circumstances: One of the main challenges facing the Other Vaccines market in South America is the high cost of these vaccines, which can be a barrier for some customers. However, government vaccination campaigns and subsidies are helping to make these vaccines more accessible to a wider population. In addition, there is a growing trend towards private vaccination clinics, which offer a wider range of vaccines and more personalized service.

Underlying macroeconomic factors: The growth of the Other Vaccines market in South America is being driven by a number of macroeconomic factors, including increasing healthcare spending, a growing middle class, and a rising awareness of the importance of vaccination. In addition, the region is home to a number of local manufacturers, which are able to produce vaccines at a lower cost than international competitors. This is helping to drive down the cost of vaccines and make them more accessible to a wider population. Overall, the future looks bright for the Other Vaccines market in South America, with continued growth expected in the coming years.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.